

MENINGITIS A


DEADLY

EXPENSIVE

PREVENTABLE

MENINGITIS A

threatens the lives of **450 million people** across 26 countries in Africa's "Meningitis Belt," mostly children and young adults.



MENINGITIS kills within hours



THOUSANDS DIE

in years with large outbreaks.



1 in 10

die within 2 days even when antibiotics are available.



1 in 4

survivors are left with permanent disabilities such as paralysis, blindness, hearing loss, seizures, and intellectual disability.

MENINGITIS treatment is costly

for both families and nations and contributes to the cycle of poverty.



Each case of meningitis in a family results in a sudden cost of about **\$90**—what is about 3 or 4 months of the family's income.



The permanent disabilities caused by meningitis leave survivors less able to care for themselves and less likely to earn income.

The MenAfriVac® vaccine



protects against meningitis A... saving lives and money

\$0.40

MenAfriVac® became available for use in Africa in 2010 priced at just \$0.40 per dose. Over 217 million people had received the vaccine by the end of 2014.



A prevention cost of **\$0.40 per person** vs. a treatment cost of **\$90 per person**.

450 MILLION

The vaccine is targeted to protect 450 million people at risk from meningitis by 2016 and save nearly 150,000 lives.



MenAfriVac® is the first vaccine for use in Africa that can be transported and stored for as long as 4 days without refrigeration or even an ice pack. This saves money and allows for safe delivery to people in even the most remote areas.

The introduction of this vaccine is a giant step toward achieving elimination of epidemic meningitis as a public health problem in sub-Saharan Africa.



U.S. Department of
Health and Human Services
Centers for Disease
Control and Prevention